COVID-19 Funding Opportunities

Funding for Research from the CARES Act

Learn more about the CARES Act here.

Agency and page number in CARES Act CARES Appropriation Amount
p. 626 National Institute of Standards Scientific Research •  $6 M for Scientific and Technical Research funding for NISSR - Dept of Commerce
p. 627 National Oceanic and Atmospheric Adminstration Operations, Research, Facilities •  $20 M for Operations, Research and Facilities
p. 631 State & Local Law Assistance •  $850 M allocated to law enforcement agencies nationwide
p. 633 Scientific Research Funding:  National Science Foundation (NSF) •  $75M in funding toward COVID-19 related research
p. 658 Scientific Research Funding:  Department of Energy Office of Science (DOE) •  $99.5M in funding toward COVID-19 related research
p. 705 FEMA Disaster Relief Fund •  $45B appropriated to FEMA for disaster relief
p. 716 EPA -Science and Technology, research •  $2.25 M granted to EPA for Science and Technical Research
p. 719 Forest Service - Research •  $3 M appropriated to Forest Service for Research
p. 726 National Endowment for Arts 40% to states; 60% direct grants •  $75M appropriated to NEA; 60% of funds available for direct grants
p. 727 National Endowment for Humanities 40% to states; 60% direct grants •  $75M appropriated to NEA; 60% of funds available for direct grants
p. 731 DHHS -CDC surveillance, epidemiology, lab capacity, infection control, mitigation, communication, global response, health data surveillance and analytics, infrastructure modernization, infectious disease rapid response • $1.5 B for  surveillance,epidemiology, lab capacity, infection control, mitigation, communication, preparedness and response • $500 M global disease and response • $500 M health data surveillance and analytics, infrastructure modernization $300M  infectious disease rapid response reserve fund
p. 733 Scientific Research Funding:  National Institutes of Health (NIH) (see detail below) •  $945M in funding toward COVID-19 related research
p. 733 National Heart Lung Blood Institute •  $103 M appropriated for research
p. 734 National Institute  of Allergy and Infectious Diseases •  $706M appropriated for research
p. 734 National Institute of Biomedical Imaging and Bioengineering •  $60 M appropriated for research
p. 736 Substance Abuse & Mental Health - clinic expansion, suicide prevention •  $425 M appropriated to DHHS for Certified Community Behavioral Health Clinic Expansion Grants and Suicide Prevention Programs
p. 746 Public Health & Social Services Emergency fund- National Stockpile, Hospital Preparedness Program, Biomedical Advanced Research, Development of vaccines, therapeutics, diagnostics, surge capacity. Blood supply chain assessment, workforce modernization, telehealth access and infrastructure, initial advanced manufacturing, novel dispensing, vaccine purchase •  $27.015 B appropriation to DHHS; $16 B National Stockpile, PPE & other equipment, drugs • $250 M Hospital Preparedness Program • $3.5 B Biomedical Advanced Research & Development •  Development of vaccines, therapeutics, diagnostices, surge capacity. Blood supply chain assessment, workforce modernization, telehealth access and infrastructure
p. 750 Additional funding for AIDS research, poison control •  $275 M for AIDS research, poison control and other emergency funding
p. 753 Health care providers - Temporary structures, leasing properties, med supplies, PPE, testing supplies, increased workforce and training, EOCs, retrofitting facilities. ELIGIBLE PROVIDER SUBMITS APPLICATION TO SECTY OF HHS JUSTIFYING NEED FOR PAYMENT •  $100 B for health care providers for temporary structures, leasing properties, med supplies, PPE, testing supplies, increased workforce and training, EOCs, retrofitting facilities. 

Back to Top

Internal Funding Opportunities

Stanford Seed Funding

 

Stanford RISE – Respond, Innovate, Scale, Empower

COVID-19 Crisis Response Request for Proposals

 

Stanford RISE aims to respond to the COVID-19 pandemic with solutions for our community that can help people and organizations respond to the complex medical, economic, policy and societal needs of this moment and far beyond. The purpose of this request for proposals (RFP) is to complement the scope of two recently announced RFPs designed to accelerate the prototyping of innovative medicines and to enable hypothesis-driven studies on COVID-19 patients (https://chemh.stanford.edu/programs/covid-19-response). 

Through this RFP, we seek to support ideas that have the potential to address health and wellness issues raised by the COVID-19 pandemic. These would include proposals on social, economic, or other disparities revealed by the pandemic, community-building at Stanford and beyond, and the fostering of partnerships that are relevant to the current crisis and will persist thereafter. 

 Support Provided:

Successful applicants will receive $25K-$50K (total direct) for 6-12 months. 

Deadline:

All application materials must be received by June 30, 2020.

Eligibility:

  • All Stanford faculty with PI eligibility and CEs with a PI waiver are welcome to apply. 
  • Proposals are also welcome from teams of two or more predoctoral and/or postdoctoral trainees, with the support of their advisors. 
  • Proposals from faculty will be separately reviewed from those submitted by trainees. 

Click here proposal details

 

 

Stanford ChEM-H and the Innovative Medicines Accelerator (IMA)

COVID-19 Response: Request for Proposals for Drug and Vaccine Prototyping

COVID-19 Response: Request for Proposals for Outpatient Studies on Human Subjects

Timeline:

Proposal deadline: Friday, May 29, 2020*

*LOIs do not need to be submitted to the PI’s Contract and Grants officer in OSR or the Research Process Manager in RMG for approval. All application materials must be submitted through the online application portal: https://chemh.stanford.edu/programs/covid-19-response

Eligibility:  All Stanford faculty with PI eligibility

Purpose: Stanford University’s Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines, and to enable hypothesis-driven studies on human subjects. The purpose of this request for proposals (RFP) is to leverage emerging capacity and infrastructure at Stanford to address the current COVID-19 pandemic.

COVID-19 Response: Request for Proposals for Drug and Vaccine Prototyping: Through this RFP, IMA seeks to support translational research projects that will develop scalable drug screening assays, validate novel drug targets, repurpose molecules with human safety data, or engineer new reagents that will serve as drug or vaccine prototypes for COVID-19. Competitive projects will have a strong therapeutic or prophylactic hypothesis. Projects at all stages (lead discovery, lead optimization) and modalities (small molecule, large molecule) will be considered provided that the project is driven by developing a therapy or prophylaxis for COVID-19. Basic research and pre-target identification/pre-assay development research are excluded from this RFP. https://chemh.stanford.edu/covid-19-drug-and-vaccine-prototyping

COVID-19 Response: Request for Proposals for Outpatient Studies on Human Subjects: Through this RFP, IMA seeks to support research projects aimed at testing hypotheses in human subjects that, if validated, have the potential to yield powerful new tools for the modeling, diagnosis, or management of COVID-19 in individuals or populations. Competitive projects will have a strong mechanistic basis and will leverage Stanford’s newly established outpatient COVID-19 Clinical and Translational Research Unit (CTRU), where outpatients can be safely tested and/or treated. 

https://chemh.stanford.edu/covid-19-outpatient-studies-human-subjects

Support Provided:

Successful applicants will receive $50K-$100K (total direct) for 6-12 months with the possibility to apply for follow-up funding, contingent upon progress and scientific needs to address the rapidly evolving COVID-19 pandemic. Projects may be fully or partially funded. Projects in the “Outpatient Studies on Human Subjects” track will have access to the COVID-19 CTRU.

Selection Process:

Proposals will be reviewed by a faculty panel knowledgeable in translational research. Projects in the “Drug and Vaccine Prototyping” track will be evaluated based on the strength of the evidence for the drug or vaccine hypothesis for the treatment or prevention of COVID-19, novelty, availability of materials and facilities, and achievable goals. Projects in the “Outpatient Studies on Human Subjects” track will be evaluated based on the proposal's potential to advance understanding of the pathogenesis, population biology, diagnosis, or management of COVID-19 in human subjects, access to and use of human subjects or samples, availability of materials and facilities, and achievable goals.

Questions and Contact Info:

Elizabeth Sefton, Ph.D. Scientific Program Manager, Stanford ChEM-H esefton@stanford.edu

 

Stanford Human-Centered Artificial Intelligence Center (HAI)

COVID-19 Collaboration Opportunities

Back to Top

NIH/HHS Funding Opportunities

 

COVID-19 Funding and Funding Opportunities – Open Mike Blog

Dr. Michael Lauer is NIH's Deputy Director for Extramural Research, serving as the principal scientific leader and advisor to the NIH Director on the NIH extramural research program.

Number

Title

Participating Organizations

Release Date

NOT-OD-20-107 Notice of Special Interest (NOSI): Administrative Supplements to Existing NIH ECHO Cooperative Agreements (Admin Supp - Clinical Trial Not Allowed) for Coronavirus Disease 2019 (COVID-19) – related Research Office of The Director, National Institutes of Health (OD) May 27, 2020
NOT-AT-20-012 Notice of Special Interest (NOSI): Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19) National Center for Complementary and Integrative Health (NCCIH) Office of Research on Women’s Health (ORWH ) May 26, 2020
RFA-RM-20-020 NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional) Office of Strategic Coordination (Common Fund) May 21, 2020
RFA-RM-20-021 NIH Directors Emergency Early Independence Awards (DP5 Clinical Trial Optional) Office of Strategic Coordination (Common Fund) May 21, 2020
NOT-AI-20-051 Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) National Institute of Allergy and Infectious Diseases (NIAID) May 19, 2020
FA-RM-20-020 NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional) Office of Strategic Coordination (Common Fund) May 21, 2020
RFA-RM-20-021 NIH Directors Emergency Early Independence Awards (DP5 Clinical Trial Optional) Office of Strategic Coordination (Common Fund) May 21, 2020
NOT-AI-20-051 Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) National Institute of Allergy and Infectious Diseases (NIAID) May 19, 2020
NOT-CA-20-066 Notice of Intent to Publish a Funding Opportunity Announcement for Serological Sciences Centers of Excellence National Cancer Institute (NCI) May 15, 2020
NOT-OD-20-103 Notice of Additional Due Date and Additional “Areas of Focus Especially of Interest” of PAR-19-373 and PAR-19-384, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)" NIH Basic Behavioral and Social Science Opportunity Network (OPPNET) National Institute on Aging (NIA) National Institute on Alcohol Abuse and Alcoholism (NIAAA) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institute on Drug Abuse (NIDA) National Institute of Mental Health (NIMH) National Institute of Neurological Disorders and Stroke (NINDS) National Institute of Nursing Research (NINR) National Institute on Minority Health and Health Disparities (NIMHD) National Center for Complementary and Integrative Health (NCCIH) Office of Behavioral and Social Sciences Research (OBSSR) May 7, 2020
NOT-DE-20-023 Notice of Special Interest (NOSI): Infrastructure Access for Research on Coronavirus Disease 2019 (COVID-19) Conducted in the National Dental Practice-Based Research Network National Institute of Dental and Craniofacial Research (NIDCR) May 5, 2020
NOT-DE-20-022 Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR National Institute of Dental and Craniofacial Research (NIDCR) Office of Research on Women's Health (ORWH) May 5, 2020
       
NOT-NS-20-051 Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System National Institute of Neurological Disorders and Stroke (NINDS) April 30, 2020
PAR-20-177 Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed) National Institute of Allergy and Infectious Diseases (NIAID) April 30, 2020
PAR-20-178 Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) National Institute of Allergy and Infectious Diseases (NIAID) April 30, 2020
NOT-CA-20-054 Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis National Cancer Institute (NCI) April 28, 2020
NOT-RM-20-015 Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Office of Strategic Coordination (Common Fund) April 27, 2020
NOT-TR-20-028 Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs National Center for Advancing Translational Sciences (NCATS) April 23, 2020
OT-TR-20-028 Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs National Center for Advancing Translational Sciences (NCATS) April 23, 2020
BAA-20-100-SOL-0002

BARDA Funding for COVID-19 Projects

Focus areas include products and services related to vaccines, diagnostics or therapeutics.  

BARDA's Division of Research, Innovation & Ventures (DRIVe)   
NOT-AA-20-011 Notice of Special Interest:  Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA National Institute on Alcohol Abuse and Alcoholism (NIAAA) April 16, 2020
NOT-LM-20-010 Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) National Library of Medicine (NLM) April 16, 2020
NOT-NS-20-046 Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for the Establishment and Maintenance of a Research Database for Neurological Manifestations of the SARS-CoV-2 National Institute of Neurological Disorders and Stroke (NINDS) April 14, 2020
NOT-OD-20-097 Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences many institutes April 13,2020
NOT-DK-20-020 Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK's Mission National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) April 9, 2020
NOT-MD-20-019 Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities National Institute on Minority Health and Health Disparities (NIMHD) April 9, 2020
NOT-TR-20-017 Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus National Center for Advancing Translational Sciences (NCATS) April 9, 2020
NOT-MH-20-047 Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus National Institute of Mental Health (NIMH) April 9, 2020
NOT-TR-20-016 Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus National Center for Advancing Translational Sciences (NCATS) April 9, 2020
NOT-CA-20-043 Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19) National Cancer Institute (NCI) April 9, 2020
NOT-ES-20-015 Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) National Institute of Environmental Health Sciences (NIEHS) April 9, 2020
NOT-DK-20-018 Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) April 9, 2020
NOT-DC-20-004 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) National Institute on Deafness and Other Communication Disorders (NIDCD) April 9, 2020
NOT-HL-20-759 NHLBI Announces Availability of Frequently Asked Questions (FAQs) for NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) National Heart, Lung, and Blood Institute (NHLBI) April 8, 2020
NOT-AG-20-022 Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) National Institute on Aging (NIA) National Institute of Mental Health (NIMH) April 2, 2020
NOT-HG-20-030 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus National Human Genome Research Institute (NHGRI) March 31, 2020
NOT-ES-20-014 Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed) National Institute of Environmental Health Sciences (NIEHS) March 27, 2020
NOT-TR-20-012 Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) National Center for Advancing Translational Sciences (NCATS) March 27, 2020
NOT-AI-20-034 Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome National Institute of Allergy and Infectious Diseases (NIAID) March 25, 2020
NOT-AI-20-040 Notice of Early Expiration of “Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 National Institute of Allergy and Infectious Diseases (NIAID) March 25, 2020
NOT-GM-20-025 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 National Institute of General Medical Sciences (NIGMS) March 25, 2020
NOT-TR-20-011 Notice of Special Interest (NOSI) Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need National Center for Advancing Translational Sciences (NCATS) March 24, 2020
NOT-DA-20-047 Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus National Institute on Drug Abuse (NIDA) March 19, 2020
NOT-HL-20-757 Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) National Heart, Lung, and Blood Institute (NHLBI) March 17, 2020
NOT-AI-20-030 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of General Medical Sciences (NIGMS) February 6, 2020

Resources

 

Back to Top

Other Sources of Funding

Faculty (or researchers with PI status) with primary appointments at UC Berkeley, UC San Francisco, UC Davis, Stanford, and equivalent local research institutions are eligible to apply.

See more info and applyhttps://webportalapp.com/appform/login/igi-covid19-fund Deadline: Friday, May 1st, 2020

Program Announcement – for current Research Awardees

Program Announcement – for current Engagement Awardees

Program Announcement – for current Dissemination and Implementation Awardees

Back to Top

Click the Funding navigation menu at the top of this page.

  1. Find the mosaic tile entitled "Search Funding Database"
  2. Click More at the bottom of the tile

3. You will land on this page, select Opportunities and put your search keywords in the box.

4. You will land on the search result page.  On the top left click "create new alert for this search".  Fill out the search criteria.

5. You will receive emails according to what you scheduled in Step 4 above.  Note the email will come with the title "do-not-reply@deepwebaccess.com", see image below.

 

Back to Top